Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Acquisitions In Brief

This article was originally published in The Gray Sheet

Executive Summary

ConvaTec poised to combine with Unomedical: Ostomy and wound care device business ConvaTec, which is being acquired by private equity firms Nordic Capital Fund VII and Avista Capital Partners from Bristol-Myers Squibb under a May 2 deal, will be combined with Danish single-use medical device maker Unomedical, currently owned by Nordic Capital Fund IV, after the ConvaTec deal closes in the third quarter, the investor groups announce June 27. The combination will enable Unomedical to benefit from Skillman, N.J.-based ConvaTec's "global presence and size," and will continue to be known as ConvaTec, the firms state. ConvaTec has annual sales of $1.15 billion, while Unomedical has revenues of about $418 million, based on current exchange rates. Bristol is sharpening its pharma focus (1"The Gray Sheet" May 5, 2008, In Brief)

You may also be interested in...



New Investment Firm CMI Seeks Out Surgical Device, Test Makers

Acquisition of in vitro diagnostic and surgical device companies will be the primary focus of newly-formed private investment firm Constitution Medical Investors, headed by former Cytyc execs Patrick Sullivan and Daniel Levangie

New Investment Firm CMI Seeks Out Surgical Device, Test Makers

Acquisition of in vitro diagnostic and surgical device companies will be the primary focus of newly-formed private investment firm Constitution Medical Investors, headed by former Cytyc execs Patrick Sullivan and Daniel Levangie

Bristol-Myers Squibb divests ConvaTec

Drug maker Bristol divests its ostomy and wound care device business to private equity firms Nordic Capital Fund VII and Avista Capital Partners for $4.1 billion May 2. Avista previously acquired Bristol's imaging agent franchise for $525 million in December (1"The Gray Sheet" Jan. 7, 2008, p. 22). The moves are part of Bristol's broader effort to sharpen its focus on drugs

Latest News
See All
UsernamePublicRestriction

Register

MT026260

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel